Is Developing a Chlamydia Vaccine Worth the Cost?


A chlamydia vaccine would cut infection rates, but cost millions.

Chlamydia trachomatis (C. trachomatis), the infection that causes chlamydia, is the most common bacterial sexually transmitted infection in the United States with nearly three million cases, estimated by the US Centers for Disease Control and Prevention (CDC). Although infection rates are growing, does a chlamydia vaccine make sense from a cost perspective?

Jared Ditkowsky, MD candidate, and colleagues from SUNY Downstate Department of Pediatrics in Brooklyn, New York examined this point and presented their findings at the annual meeting of the American Academy of Allergy, Asthma, and Immunology (AAAAI 2017) in Atlanta, Georgia.

There currently isn’t a vaccine for chlamydia, and the CDC estimated $701 million spent in medical costs for the infection in 2010. Available screening programs aren’t widely affordable and developing a vaccine would cost a substantial amount of time and funds. But if a chlamydia vaccination program were to be created and implemented, the researchers say this is what would happen.

“We examined the impact of a potential chlamydia vaccination program by creating a decision analysis model to estimate the effect of vaccination on chlamydia-associated costs, morbidity, and mortality,” Ditkowsky and team explained.

Using a Markov Model (TreeAge Software), the researchers considered American women over the age of 9. They calculated chlamydia-associated costs, morbidity, and mortality over 17 years in mothers and fetus/neonates. Two scenarios were considered: chlamydial vaccination program vs. no chlamydial vaccination program.

“Base case analysis vaccine efficacy and coverage were set to those of HPV in the US, with efficacy and coverage, as well as other variables in the model, ranged in sensitivity analyses,” the researchers said.

During that 17-year period, a chlamydial vaccination program would cost $661 million for a total of 2,009,200 women. On the other hand, no vaccination program over that span of time would be $39 million less—$622 million. The analysis model found that the vaccination program would prevent 31,000 chlamydia cases and 21 spontaneous abortions caused by chlamydia.

Although a chlamydia vaccination program would add cost to the healthcare system, it would also help a significant amount of morbidity and mortality linked to the infection.

The study, “The Cost Effectiveness of a Chlamydia Trachomatis Vaccination Program in young Women in the United States,” was published in The Journal of Allergy and Clinical Immunology.

>>> More AAAAI 2017 Coverage Here

Related Videos
Oriana Damas, MD | Credit: University of Miami Miller School of Medicine
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
| Image Credit: Massachusetts General Hospital
Marla Dubinsky, MD | Credit: LinkedIn
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
© 2024 MJH Life Sciences

All rights reserved.